MedEvolve adds Jim Crook and Jon Phillips to the Board of Directors

– USA, AR – MedEvolve, Inc., a national provider of specialty-specific practice management (PM) and electronic health record (EHR) software, and revenue cycle management (RCM) services, announced today the addition of Jim Crook and Jon Phillips to the company’s Board of Directors. The two new board members have a wealth of knowledge and experience building healthcare IT companies and will help guide the company’s growth strategy.

“I have known Jim and Jon for many years and I am excited to add their extensive governance experience and deep industry knowledge to the MedEvolve Board,” said Mike Schiller, President and CEO of MedEvolve. “With their combined experience and impressive past performance in the healthcare industry, I am confident their guidance will help position MedEvolve for future expansion.”

Jim Crook has over 35 years of leadership experience with a strong track record of growing companies in healthcare IT. Currently, Mr. Crook is a private equity investor in several healthcare IT companies and serves on multiple related boards, including MediRevv, OpenTempo, RCxRules and Arcadia Healthcare Solutions. He is also on the advisory board of Peloton Equity, LLC, a healthcare growth capital company, and a member of the Colby College Board of Trustees. He began his career with IBM, followed by 25 years with IDX Systems Corporation where he held a number of executive operating roles, including President and CEO. IDX was acquired by GE Healthcare in 2006.

Jonathan Phillips has over two decades of experience providing financial advisory and strategic consulting services to leading healthcare organizations. Mr. Phillips founded Healthcare Growth Partners (HGP) in 2005, where he continues to serve as Partner and Managing Director. Prior to HGP, Mr. Phillips was a Vice President in the Healthcare Investment Banking Group at William Blair and Company, and he served in various roles in the healthcare practice of Deloitte Consulting for more than five years. Currently, he serves as Chairman of Streamline Health, and is an active member of the boards of other healthcare companies, including Vivify Health, Conversio Health, Lightbeam Health Solutions, PatientBond and Cordata Health. Throughout his career, Mr. Phillips has provided strategic and financial advisory services to over one hundred and fifty clients in the healthcare industry, including representing clients in mergers and acquisitions and equity financing transactions with an aggregate value of over $2.5 billion.

“We have made great strides over the last year to structure the company and position it as a platform for growth,” said Dr. William Hefley, Jr., Chairman of the Board for MedEvolve. “The addition of Jim and Jon to our board, two highly regarded experts and strategic advisors in healthcare IT, will provide a new level of knowledge and insight that will help us further accelerate our pace of expansion.”

About MedEvolve

MedEvolve, Inc. has served the practice management, EHR and revenue cycle management needs of its clients for over 20 years. Today, the company serves over 600 specialty practices with more than 3,500 healthcare providers. MedEvolve enables practices to work faster and with more accuracy through practice management and EHR solutions that can be implemented as on premise solutions or a subscription (SaaS) service, resulting in a quicker payment process and overall improved patient and staff experiences. MedEvolve also provides outsourced revenue cycle management (RCM) and medical billing services, along with a unique Practice DNA (Do it Now, Accurately) consultative approach, to help clients anticipate and benefit from the changes that now define the healthcare industry.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>